Form 8-K - Current report:
SEC Accession No. 0001213900-24-007723
Filing Date
2024-01-30
Accepted
2024-01-30 11:29:52
Documents
16
Period of Report
2024-01-30
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea192451-8k_estrella.htm   iXBRL 8-K 30416
2 PRESS RELEASE, DATED JANUARY 30, 2024 ea192451ex99-1_estrella.htm EX-99.1 6966
  Complete submission text file 0001213900-24-007723.txt   260356

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE esla-20240130.xsd EX-101.SCH 3863
4 XBRL DEFINITION FILE esla-20240130_def.xml EX-101.DEF 26753
5 XBRL LABEL FILE esla-20240130_lab.xml EX-101.LAB 36958
6 XBRL PRESENTATION FILE esla-20240130_pre.xml EX-101.PRE 25377
17 EXTRACTED XBRL INSTANCE DOCUMENT ea192451-8k_estrella_htm.xml XML 5998
Mailing Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608 (510) 318-9098
Estrella Immunopharma, Inc. (Filer) CIK: 0001844417 (see all company filings)

EIN.: 861314502 | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-40608 | Film No.: 24576571
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)